NCT03510390COMPLETEDanonymous

Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation

Sponsor

Source record

Insel Gruppe AG, University Hospital Bern

Phase

Source record

Modality

AI-normalized

small molecule

Target

AI-normalized

Head and Neck Squamous Cell Carcinoma

Indication / condition

AI-normalized

Head and Neck Cancer

Intervention

Source record

Metformin

Related intelligence directories

Indication directory: Head and Neck Cancer Modality directory: small molecule Target directory: Head and Neck Squamous Cell Carcinoma

Source & freshness

Source record

NCT ID

NCT03510390

Original source

ClinicalTrials.gov

Source last updated

Nov 18, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03510390

Title

Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation

Sponsor

Insel Gruppe AG, University Hospital Bern

Status

COMPLETED

Phase

Condition raw

Head and Neck Cancer

Condition normalized

Head and Neck Cancer

Modality raw

Head and Neck Cancer

Modality normalized

small molecule

Target raw

Head and Neck Squamous Cell Carcinoma

Target normalized

Head and Neck Squamous Cell Carcinoma

Interventions

Metformin

Public preview

Source record

This study investigates the effect of Metformin on tissue oxygenation in patients with oral cavity squamous cell carcinoma. The trial aims to establish whether Metformin can reduce hypoxia in tumor tissues, potentially improving treatment outcomes and response to radiation therapy.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03510390

Status

COMPLETED

Phase

Sponsor

Insel Gruppe AG, University Hospital Bern

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedNov 18, 2021

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03510390

Indication

Head and Neck Cancer

Modality

small molecule

Target

Head and Neck Squamous Cell Carcinoma

Intervention

Metformin

Source record